Strata Skin Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
$SSKN
Medical/Dental Instruments
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 20, 2025
(Exact Name of Registrant Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 215 -619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
| Item 7.01. |
Regulation FD Disclosure.
|
On March 20, 2025, STRATA Skin Sciences, Inc. (the “Company”) issued a press release
announcing the publication of a clinical study entitled “Excimer Laser Penetrates Deeper into Hair Follicles and Activates More Melanocyte Lineage Cells than Excimer Light,” authored by distinguished
researchers from the Nippon Medical School and published in the peer reviewed Journal of Nippon Medical School, which study demonstrates that despite two devices producing
same 308-nm wavelength, the distinct technological characteristics between two devices can have significant impact on the clinical outcomes. Notably, the excimer laser exhibits laser properties (monochromatic coherent light) and unique device
specifications (a high frequency of 400 Hz and a remarkably high irradiance that leads to cellular differences such as deeper penetration, greater activation of melanocyte lineage cells (melanocyte stem cells (McSCs) and melanoblasts) resulting in
superior clinical outcomes in terms of greater pigmentation and fewer epidermal side effects relative to excimer light. This study provides further scientific evidence that the modality generating UVB light has significant impact on the clinical
outcomes of a device.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth in this item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18
of the Securities Exchange Act or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth
by specific reference in any such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits.
The following press release is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be “filed”:
|
Exhibit No.
|
Exhibit Description
|
|
Press release dated March 20, 2025, issued by Strata Skin Sciences, Inc.
|
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
STRATA SKIN SCIENCES, INC.
|
|||
|
Date: March 20, 2025
|
By:
|
/s/ John Gillings
|
|
|
John Gillings
|
|||
|
Chief Accounting Officer
|
|||